RhumbLine Advisers
LYRA

RhumbLine Advisers’s LYRA THERAPEUTICS INC LYRA Stock Holding History

RhumbLine Advisers’s Portfolio LYRA Stock Details LYRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-1,754
Closed -$11K – 4211
2025
Q1 		$11K Buy
1,754
+929
+113% +$8.69K ﹤0.01% 3822
2024
Q4 		$8.49K Hold
825
– – ﹤0.01% 3898
2024
Q3 		$10.6K Sell
825
-43
-5% -$632 ﹤0.01% 3881
2024
Q2 		$12K Buy
868
+862
+14,367% +$97.4K ﹤0.01% 3953
2024
Q1 		$1.84K Hold
6
– – ﹤0.01% 4096
2023
Q4 		$1.55K Hold
6
– – ﹤0.01% 4116
2023
Q3 		$1.16K Hold
6
– – ﹤0.01% 4168
2023
Q2 		$1.22K Buy
+6
New +$833 ﹤0.01% 4271

Other funds holding LYRA

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State of Wisconsin Investment Board
State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RhumbLine Advisers's LYRA Position: Q2 2025 in Review

RhumbLine Advisers sold out of LYRA THERAPEUTICS INC (LYRA) in Q2 2025, closing a stake of 1,754 shares — an estimated $11K sold.

RhumbLine Advisers first reported a position in LYRA in Q2 2023 and held it in 8 quarters. The position peaked at $12K in Q2 2024. 30 funds tracked by Wall St. Rank hold LYRA as of Q2 2025.

  • RhumbLine Advisers reported no remaining LYRA THERAPEUTICS INC position as of Q2 2025 after selling out during the quarter.
  • RhumbLine Advisers sold 1,754 LYRA THERAPEUTICS INC shares in Q2 2025, an estimated $11K.
  • RhumbLine Advisers first reported a position in LYRA THERAPEUTICS INC in Q2 2023 and held it in 8 quarters.
  • RhumbLine Advisers's LYRA THERAPEUTICS INC position peaked at $12K in Q2 2024.
  • 30 funds tracked by Wall St. Rank held LYRA THERAPEUTICS INC as of Q2 2025.

Based on RhumbLine Advisers's 13F filing for Q2 2025, filed 12 Aug 2025.